DEF: Azitra 2026 Proxy: Share Increase and Reverse Split Plan

Azitra, Inc. seeks shareholder approval for a massive authorized share increase, reverse stock splits, and ratification of recent private placement financing.

Summary

• The company is holding its 2026 Annual Meeting on June 4, 2026, to address critical capital and governance matters.
• Key proposals include increasing authorized common stock from 200 million to 750 million shares.
• Shareholders are asked to authorize the Board to effect one or more reverse stock splits at ratios between 1-for-2 and 1-for-30.
• The company seeks ratification of recent private placement agreements with Alumni Capital LP (November 2025) and March 2026 investors to allow issuance of shares exceeding 19.99% of outstanding stock.
• Proposal 7 requests an amendment to the 2023 Stock Incentive Plan to increase the authorized share reserve by 14 million shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a distressed situation where the company is heavily reliant on dilutive financing and reverse splits to maintain its listing and operational viability.

Positives

• Secured approximately $1.5 million in gross proceeds from the November 2025 private placement.
• Secured approximately $10.5 million in initial gross proceeds from the March 2026 private placement.
• Potential for an additional $20.9 million in gross proceeds from the March 2026 warrants if exercised for cash.
• The proposed reverse stock split aims to maintain compliance with NYSE American minimum trading price requirements and avoid delisting.

Negatives

• Significant dilution risk for existing shareholders due to the proposed increase in authorized shares and potential conversion of Series A Preferred Stock and exercise of various warrants.
• The company acknowledges that existing cash and cash equivalents are insufficient to fund operations through the next twelve months.
• The company has a history of reverse stock splits (July 2024 and August 2025), indicating persistent downward pressure on share price.
• The company is contractually obligated to hold additional stockholder meetings every 180 days if Proposal 6 is not approved, increasing legal and administrative costs.

Risks

• Failure to obtain shareholder approval for Proposals 5 and 6 could jeopardize the company's ability to execute its business plan or fund operations.
• If capital is not raised in the near term, the company may need to curtail or cease operations and potentially seek bankruptcy protection.
• The reverse stock split may not successfully increase the share price or maintain compliance with NYSE American listing standards.
• The company faces potential delisting if its share price remains low or if it fails to meet other continued listing requirements, such as minimum stockholder equity.

Future Outlook

The company states that its current cash and cash equivalents are insufficient to fund operations through the next twelve months and that it requires additional capital to fund ongoing product development and general corporate purposes.

Management Comments

• The Board believes it is advisable and in our best interest to increase the number of authorized shares of common stock to give us greater flexibility in considering and planning for future corporate needs.
• The Board strongly believes that the approval of multiple Reverse Stock Splits is necessary to maintain our listing on the NYSE American.
• The Board has determined that the March Purchase Agreement is advisable and in the best interests of the Company and its stockholders because it provides the Company with a reliable source of capital at a lower cost compared to other sources.

Industry Context

StockSavvy.ai notes that Azitra's reliance on frequent capital raises and reverse stock splits is characteristic of early-stage, cash-burning biotechnology companies struggling to maintain exchange listing requirements while funding clinical development.

Comparison to Industry Standards

• The company's use of reverse stock splits to maintain listing compliance is a common, albeit often dilutive, strategy among micro-cap biotech firms.
• The reliance on private placements with warrants to raise capital is standard for companies with limited access to traditional debt or equity markets.
• The proposed increase in authorized shares is a standard defensive and operational measure for companies needing to issue equity to survive.

Corporate Governance

Related Party Transactions

• Francisco Salva (CEO) participated in the March 2026 PIPE financing, purchasing $500,000 of securities.

Stakeholder Impact

• Shareholders face significant dilution from the proposed share increase and potential warrant exercises.
• Employees and consultants may benefit from the increased share reserve for incentive awards.
• Creditors and investors in the March 2026 PIPE financing gain potential equity upside if the company remains viable.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 4, 2026.
• File a Certificate of Amendment to increase authorized shares if Proposal 2 is approved.
• Potentially effect one or more reverse stock splits if Proposal 3 is approved.
• File a Registration Statement on Form S-8 for the increased share reserve under the 2023 Plan if Proposal 7 is approved.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by the need for repeated reverse splits and massive share dilution to maintain listing and fund operations. The high risk of further dilution and the potential for delisting make this a high-risk, low-reward investment for most institutional investors.

Keywords

Azitra, biotechnology, proxy statement, reverse stock split, capital raise, shareholder meeting, NYSE American, equity incentive plan